Peru is an important and fast-growing pharmaceutical market in Latin America, valued at over $3 billion USD and expanding at approximately 7-9% annually. Driven by a population of over 33 million across a diverse geographic and cultural landscape, Peru presents distinct challenges and opportunities for healthcare market research. Lima concentrates the majority of pharmaceutical activity, multinational affiliates, and specialist physician networks, while the interior and high-altitude regions present underserved populations with distinct disease profiles and access challenges.
DIGEMID (Dirección General de Medicamentos, Insumos y Drogas) operates under MINSA (Ministerio de Salud) as Peru's primary pharmaceutical regulatory authority, overseeing drug registration, clinical trial authorisation, and pharmacovigilance. Peru's public health coverage is split between SIS (Seguro Integral de Salud) — which targets low-income and vulnerable populations — and EsSalud (Seguro Social de Salud del Perú), which provides social health insurance to formal-sector workers and their families. Together, these systems cover the majority of the population, though out-of-pocket expenditure remains significant for innovative and branded therapies.
Peru faces a substantial disease burden including high rates of tuberculosis (one of the highest in the Americas), diabetes, cardiovascular disease, and cancer. Growing clinical trial activity and Lima's emergence as a LATAM pharma hub have increased demand for high-quality primary healthcare research. Peru's multicultural population — Spanish and Quechua-speaking communities across diverse geographic zones — requires culturally sensitive research design and fieldwork protocols. The right healthcare research partner must combine DIGEMID regulatory knowledge, SIS/EsSalud system awareness, and genuine Peru-specific fieldwork capability.